-
Something wrong with this record ?
Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic
R. Chlibek, J. Smetana, K. Kybicová, M. Malikova, FJ. Angulo, A. Loew-Baselli, Y. Tan, A. Ondřejíček, G. Brestrich, A. Pilz, JC. Moïsi, JH. Stark
Language English Country Germany
Document type Journal Article
- MeSH
- Borrelia burgdorferi Group * immunology isolation & purification MeSH
- Adult MeSH
- Enzyme-Linked Immunosorbent Assay * MeSH
- Immunoglobulin G * blood MeSH
- Immunoglobulin M * blood MeSH
- Incidence MeSH
- Middle Aged MeSH
- Humans MeSH
- Lyme Disease * epidemiology microbiology blood MeSH
- Adolescent MeSH
- Young Adult MeSH
- Prevalence MeSH
- Antibodies, Bacterial * blood MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Seroepidemiologic Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
INTRODUCTION: Lyme borreliosis (LB), an infection caused by Borrelia burgdorferi sensu lato (Bbsl), is the most common tick-borne disease in Europe. To further characterize the LB burden in the Czech Republic, we conducted a seroprevalence study and estimated the incidence of symptomatic Bbsl infections. METHODS: Anti-Bbsl IgM and IgG antibodies were detected in sera collected from the adult population in 2011 -2012 by enzyme-linked immunosorbent assay and immunoblot tests at the National Reference Laboratory. The incidence of symptomatic Bbsl infections was estimated from the seroprevalence results and the symptomatic proportion and duration of persistence of anti-Bbsl IgG antibodies in Bbsl-infected individuals. Surveillance under-detection of symptomatic Bbsl infections was estimated by comparing surveillance-reported and seroprevalence-based incidence. RESULTS: Samples from 1996 adults were tested; the median age (range) was 45 (18 -87) years; 1037 (52.0 %) were female. The prevalence (with 95 % confidence interval) of anti-Bbsl IgG, and IgM and/or IgG (IgM/IgG) antibodies was 6.3 % (5.3 -7.5 %), and 9.5 % (8.3 -10.9 %), respectively. The IgM/IgG prevalence was 7.8 % (6.5 -9.2 %) in Bohemia and 15.3 % (12.2 -19.0 %) in Moravia. There were an estimated 30,563 (26,550 -34,962) symptomatic incident Bbsl infections in adults in the Czech Republic in 2012, for an incidence of 352.2 (306.0 -402.9) symptomatic Bbsl infections per 100,000 adults per year. There were an estimated 11 (10 -13) symptomatic Bbsl infections for each surveillance-reported LB case in the Czech Republic in 2012. CONCLUSIONS: There is high incidence of symptomatic Bbsl infections in the Czech Republic, particularly in Moravia. Interventions are needed to address the substantial burden of LB in the Czech Republic.
Evidence Generation Statistics Pfizer Inc 1 Portland Street Cambridge MA 02139 USA
Military Medical Faculty University of Defence Trebesska 1575 Hradec Kralove 500 01 Czech Republic
Pfizer spol s r o Stroupežnického 3191 17 Praha 5 150 00 Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009699
- 003
- CZ-PrNML
- 005
- 20250429134856.0
- 007
- ta
- 008
- 250415e20250103gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijmm.2024.151644 $2 doi
- 035 __
- $a (PubMed)39778258
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Chlibek, Roman $u Military Medical Faculty, University of Defence, Trebesska 1575, Hradec Kralove 500 01, Czech Republic. Electronic address: roman.chlibek@unob.cz
- 245 10
- $a Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic / $c R. Chlibek, J. Smetana, K. Kybicová, M. Malikova, FJ. Angulo, A. Loew-Baselli, Y. Tan, A. Ondřejíček, G. Brestrich, A. Pilz, JC. Moïsi, JH. Stark
- 520 9_
- $a INTRODUCTION: Lyme borreliosis (LB), an infection caused by Borrelia burgdorferi sensu lato (Bbsl), is the most common tick-borne disease in Europe. To further characterize the LB burden in the Czech Republic, we conducted a seroprevalence study and estimated the incidence of symptomatic Bbsl infections. METHODS: Anti-Bbsl IgM and IgG antibodies were detected in sera collected from the adult population in 2011 -2012 by enzyme-linked immunosorbent assay and immunoblot tests at the National Reference Laboratory. The incidence of symptomatic Bbsl infections was estimated from the seroprevalence results and the symptomatic proportion and duration of persistence of anti-Bbsl IgG antibodies in Bbsl-infected individuals. Surveillance under-detection of symptomatic Bbsl infections was estimated by comparing surveillance-reported and seroprevalence-based incidence. RESULTS: Samples from 1996 adults were tested; the median age (range) was 45 (18 -87) years; 1037 (52.0 %) were female. The prevalence (with 95 % confidence interval) of anti-Bbsl IgG, and IgM and/or IgG (IgM/IgG) antibodies was 6.3 % (5.3 -7.5 %), and 9.5 % (8.3 -10.9 %), respectively. The IgM/IgG prevalence was 7.8 % (6.5 -9.2 %) in Bohemia and 15.3 % (12.2 -19.0 %) in Moravia. There were an estimated 30,563 (26,550 -34,962) symptomatic incident Bbsl infections in adults in the Czech Republic in 2012, for an incidence of 352.2 (306.0 -402.9) symptomatic Bbsl infections per 100,000 adults per year. There were an estimated 11 (10 -13) symptomatic Bbsl infections for each surveillance-reported LB case in the Czech Republic in 2012. CONCLUSIONS: There is high incidence of symptomatic Bbsl infections in the Czech Republic, particularly in Moravia. Interventions are needed to address the substantial burden of LB in the Czech Republic.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a imunoglobulin G $x krev $7 D007074
- 650 12
- $a lymeská nemoc $x epidemiologie $x mikrobiologie $x krev $7 D008193
- 650 _2
- $a séroepidemiologické studie $7 D016036
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a imunoglobulin M $x krev $7 D007075
- 650 12
- $a protilátky bakteriální $x krev $7 D000907
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 12
- $a Borrelia burgdorferi komplex $x imunologie $x izolace a purifikace $7 D015748
- 650 12
- $a ELISA $7 D004797
- 650 _2
- $a prevalence $7 D015995
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Smetana, Jan $u Military Medical Faculty, University of Defence, Trebesska 1575, Hradec Kralove 500 01, Czech Republic. Electronic address: jan.smetana@unob.cz
- 700 1_
- $a Kybicová, Kateřina $u National Reference Laboratory for Lyme Borreliosis, National Health Institute, Šrobárova 49/48, Prague 10, 100 00, Czech Republic. Electronic address: katerina.kybicova@szu.cz
- 700 1_
- $a Malikova, Martina $u Military Medical Faculty, University of Defence, Trebesska 1575, Hradec Kralove 500 01, Czech Republic. Electronic address: martina.malikova@unob.cz
- 700 1_
- $a Angulo, Frederick J $u Global Vaccines and Anti-infectives Medical Affairs, Pfizer Inc., Collegeville, 500 Arcola Road, PA 19426, USA. Electronic address: frederick.angulo@pfizer.com
- 700 1_
- $a Loew-Baselli, Alexandra $u Global Vaccines and Anti-infectives Medical Affairs, Pfizer Corporation Austria, Floridsdorfer Hauptstraße 1, Vienna 1210, Austria. Electronic address: alexandra.loew-baselli@pfizer.com
- 700 1_
- $a Tan, Ye $u Evidence Generation Statistics, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA. Electronic address: ye.tan@pfizer.com
- 700 1_
- $a Ondřejíček, Aleš $u Pfizer spol. s r.o., Stroupežnického 3191/17, Praha 5, 150 00, Czech Republic. Electronic address: ales.ondrejicek@pfizer.com
- 700 1_
- $a Brestrich, Gordon $u Global Vaccines and Anti-infectives Medical Affairs, Pfizer Pharma GmbH, Friedrichstraße, Berlin 110-10117, Germany. Electronic address: gordon.brestrich@pfizer.com
- 700 1_
- $a Pilz, Andreas $u Global Vaccines and Anti-infectives Medical Affairs, Pfizer Corporation Austria, Floridsdorfer Hauptstraße 1, Vienna 1210, Austria. Electronic address: andreas.pilz@pfizer.com
- 700 1_
- $a Moïsi, Jennifer C $u Global Vaccines and Anti-infectives Medical Affairs, 23 Avenue du Docteur Lannelongue, Paris 75014, France. Electronic address: jennifer.moisi@pfizer.com
- 700 1_
- $a Stark, James H $u Global Vaccines, and Anti-infectives Medical Affairs, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA. Electronic address: james.h.stark@pfizer.com
- 773 0_
- $w MED00005699 $t International journal of medical microbiology $x 1618-0607 $g Roč. 318 (20250103), s. 151644
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39778258 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134851 $b ABA008
- 999 __
- $a ok $b bmc $g 2311212 $s 1246780
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 318 $c - $d 151644 $e 20250103 $i 1618-0607 $m International journal of medical microbiology $n Int J Med Microbiol $x MED00005699
- LZP __
- $a Pubmed-20250415
